Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP

Journal of the American Society of Nephrology

Volumn 14, Issue 8, 2003, Pages 1990-1997

  Chander, Praveen N ^a   Rocha, Ricardo ^a,b   Ranaudo, Jeffrey ^a   Singh, Gagan ^a   Zuckerman, Andrea ^a,c   Stier, Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; CREATININE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SODIUM; SODIUM CHLORIDE;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY EXCRETION;

EID: 0041842633     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000078960.15147.05     Document Type: Article

References (47)

1. Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T: Stroke-prone spontaneously hypertensive rats as an experimental model of malignant hypertension. Virchows Arch A Pathol Anat Histol 394: 185-194, 1982
2. Shibota M, Nagaoka A, Shino A, Fujita T: Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am J Physiol 5: H409-H416, 1979
3. Stier CT Jr, Chander PN, Gutstein WH, Levine S, Itskovitz HD: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 4: 680-687, 1991
4. Camargo MJF, von Lutterotti N, Campbell WG Jr, Pecker MS, James GD, Timmermans PB, Laragh JH: Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 11: 31-40, 1993
5. Robertson AL, Khairallah PA: Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res 31: 923-931, 1972
6. Chusilp S, Hua ASP, Kincaid-Smith P: Accelerated hypertension in the rat: Relation between renin, renal vascular lesions, salt intake and blood pressure. Clin Sci Mol Med 51: 69S-71S, 1976
7. Stier CT Jr, Benter IF, Ahmad S, Zuo H, Selig N, Roethel S, Levine S, Itskovitz HD: Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 13: 115-121, 1989
8. Stier CT Jr, Mahboubi K, DiPippo VA, Levine S, Chander PN: The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Ther 260: 1410-1415, 1992
9. Stier CT Jr, Sim GJ, Mahboubi K, Shen W, Levine S, Chander PN: Prevention of stroke and hypertensive renal disease by the angiotensin II receptor antagonist DuP 753 in salt-loaded stroke-prone SHR. In: Current Advances in ACE Inhibition, 2nd Ed., edited by MacGregor GA, Sever PS, London, Churchill Livingstone, 1991, pp 252-255
10. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 46: 1346-1358, 1994
11. Quinn SJ, Williams GH: Regulation of aldosterone secretion. Ann Rev Physiol 50: 409-426, 1988
12. Ruggenenti P, Remuzzi G: Malignant vascular disease of the kidney: Nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Am J Kidney Dis 27: 459-475, 1996
13. Lombes M, Oblin ME, Gasc J-M, Baulieu EE, Farman N, Bonvalet JP: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71: 503-510, 1992
14. Golestaneh N, Klein C, Valamanesh F, Suarez G, Agarwal MK, Mirshahi M: Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 280: 1300-1306, 2001
15. Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10: 97-107, 2002
16. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998
17. Stier CT Jr, Chander PN, Zuckerman A, Rocha R: Vascular protective effect of a selective aldosterone receptor antagonist in stroke-prone hypertensive rats. Presented at the 25th Annual International Aldosterone Conference, San Diego, CA, June 10-11, 1999
18. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Mineralocorticoid antagonism reduces Ang-II induced renal injury in stroke-prone hypertensive rats [Abstract]. Am J Hypertens 11: 94, 1998
19. Stanton B, Giebisch G, Klein-Robbenhaar G, Wade J, DeFronzo RA: Effects of adrenalectomy and chronic adrenal corticosteroid replacement on potassium transport in rat kidney. J Clin Invest 75: 1317-1326, 1985
20. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999
21. Zuckerman A, Chander PN, Zeballos GA, Stier CT Jr: Regional renal nitric oxide release in stroke-prone spontaneously hypertensive rats. Hypertension 30: 1479-1486, 1997
22. Epstein M: Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 19: 829-842, 2001
23. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh F-Y, Takeda R: Production of aldosterone in isolated rat blood vessels. Hypertension 25: 170-173, 1995
24. Weihprecht H, Lorenz JN, Briggs JP, Schnermann J: Vasoconstrictor effect of angiotensin and vasopressin in isolated rabbit afferent arterioles. Am J Physiol 261: F273-F282, 1991
25. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 53: 1-46, 1974
26. Mervaala E, Muller DN, Schmidt F, Park J-K, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 35: 587-594, 2000
27. Selye H, Hall CE, Rowley EM: Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride. Can Med Assoc J 49: 88-92, 1943
28. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, Gavras I: Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Role of renin and sodium in vascular changes. Circ Res 36: 300-309, 1975
29. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, Feiner HD: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259: F598-F604, 1990
30. Sorooshian M, Olson JL, Meyer TW: Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension. Hypertension 36: 569-574, 2000
31. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227, 2000
32. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000
33. Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 41: 326-333, 1992
34. Nowaczynski W, Oliver WJ, Neel JV: Serum aldosterone and protein-binding variables in Yanomama Indians: A "no-salt" culture as compared to partially acculturated Guaymi Indians. Clin Physiol Biochem 3: 289-306, 1985
35. Conn JW, Knopf RF, Nesbit RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107: 159-172, 1964
36. Kaplan NM: Primary aldosteronism with malignant hypertension. N Engl J Med 269: 1282-1286, 1963
37. Aloia JF, Beutow G: Malignant hypertension with aldosteronoma producing adenoma. Am J Med Sci 268: 241-245, 1974
38. Beevers DG, Brown JJ, Ferriss JB, Fraser R, Lever AF, Robertson JIS, Tree M: Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med 45: 401-410, 1976
39. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJT, Williams BC, Mullins JJ: Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 46: 1528-1532, 1994
40. Möhring J, Petri M, Szokol M, Haack D, Möhring B: Effects of saline drinking on malignant course of renal hypertension in rats. Am J Physiol 230: 849-857, 1976
41. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594-597, 2000
42. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21: 929-933, 1993
43. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-β1. Eur J Pharmacol 290: 69-73, 1995
44. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828-4836, 2002
45. Fiebeler A, Schmidt F, Müller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC: Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 37: 787-793, 2001
46. Barr CS, Lang CC, Hanson J, Amott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76: 1259-1265, 1995
47. Stier CT Jr, Zuckerman A, Harashima H, Chander PN: Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone SHR [Abstract]. J Am Soc Nephrol 10: 2019, 1999